amivantamab + lazertinib

Amivantamab plus lazertinib is a fixed combination regimen of two targeted therapies for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. Amivantamab is a bispecific monoclonal antibody targeting both EGFR and MET receptors, blocking ligand binding and inducing immune-mediated cytotoxicity. Lazertinib is a third-generation, CNS-penetrant small molecule tyrosine kinase inhibitor that irreversibly inhibits mutant EGFR by covalent binding to the Cys797 residue in the ATP-binding site. The combination acts both intra- and extracellularly to inhibit tumor growth and overcome resistance mechanisms seen with single-agent EGFR inhibitors. This regimen has demonstrated superior progression-free survival and overall survival compared to osimertinib monotherapy in phase 3 clinical trials[1][2][3][4][5][6].

Brand names

Rybrevant + Lazcluze

Other names

amivantamab-vmjw + lazertinibRybrevant + LAZCLUZE